Publicaciones

  • Wesseling, J.F., Pérez-Otaño, I.  Modulating GluN3A expression in Huntington´s disease: A new NMDA receptor-based therapeutic approach?, JAMA Neurology, 11, 46-51 (2015).

  • Kehoe, Bellone, De Roo, Pérez-Otaño, I.*, Muller, D.*, GluN3A promotes dendritic spine pruning and destabilization during postnatal development, Journal of Neuroscience, 34, 9213-9221 (2014). [*Equal contribution].

  • Fiuza, M., Gonzalez-Gonzalez, MI., Pérez-Otaño, I., GluN3A expression restricts maturation of inactive synapses via direct binding to GIT1, Proc Natl Acad Sci USA, 110, 20807 (2013).

  • Yuan, T., Mameli, M., O´Connor EC, Dey, P., Verpelli, C., Sala, C., Perez-Otaño, I., Luscher, C., Bellone, C. Expression of cocaine-evoked synaptic plasticity by GluN3A-containing NMDA receptors, Neuron, 8, 1-14 (2013).

  • Marco, S., Giralt, A., Petrovic M., Pouladi, M., Torres-Peraza, J., Watanabe, M., Graham, R.K., Hayden, M.R., Wesseling, J.F., Alberch, J., Pérez-Otaño, I., Reversing aberrant GluN3A expression rescues synapse loss and motor and cognitive dysfunction in HD mouse models, Nature Medicine, 19, 1030-1038 (2013). [News and Views, p 971 same issue, Huntington´s disease: easing the traffic jam].

  • Chowdhury, D., Marco, S., Zandueta, A., Rao, Y., Haucke, V., Wesseling, JF., Tavalin, SJ., Pérez-Otaño, Tyrosine phosphorylation regulates endocytosis and surface expression of GluN3A-containing NMDARs, Journal of Neuroscience, 33, 4151-4164 (2013).

  • Roberts, A., Díez-García, J., Rodriguiz, R., López-García, I., Martínez-Turrillas, R., Picó, E., Luján, R., Henson, M.E., López-Mascaraque, L., Feng, G., Lo, D.C., Wesseling, J.F., Wetsel, W.C., Philpot, B.D., Pérez-Otaño, I.  Developmental down-regulation of NR3A-containing NMDA receptors is required for synapse maturation and memory consolidation, Neuron, 63, 342-356 (2009).  [Cited by Faculty of 1000 as Must-Read].



"Tratamos de identificar los factores que dan origen al proceso neurodegenerativo para diseñar nuevas estrategias experimentales que permitan detectar y tratar la enfermedad en fases tempranas", Dra. Isabel Pérez-Otaño, directora del programa.

Más información:

Contactar

Contacto:
Cristina Canciani
Avda. Pío XII, 53
31008 Pamplona
España

(+34) 948 194 700 Ext. 2013
canciani@unav.es